CA3119339A1 - Anellosomes for delivering intracellular therapeutic modalities - Google Patents

Anellosomes for delivering intracellular therapeutic modalities Download PDF

Info

Publication number
CA3119339A1
CA3119339A1 CA3119339A CA3119339A CA3119339A1 CA 3119339 A1 CA3119339 A1 CA 3119339A1 CA 3119339 A CA3119339 A CA 3119339A CA 3119339 A CA3119339 A CA 3119339A CA 3119339 A1 CA3119339 A1 CA 3119339A1
Authority
CA
Canada
Prior art keywords
nucleic acid
sequence
anellosome
genetic element
orf1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3119339A
Other languages
English (en)
French (fr)
Inventor
Erica Gabrielle Weinstein
Avak Kahvejian
Simon Delagrave
Nathan Lawrence YOZWIAK
Kevin James LEBO
Fernando Martin DIAZ
Dhananjay Maniklal NAWANDAR
Ryan D. TEDSTONE
Jared David PITTS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flagship Pioneering Innovations V Inc
Original Assignee
Flagship Pioneering Innovations V Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations V Inc filed Critical Flagship Pioneering Innovations V Inc
Publication of CA3119339A1 publication Critical patent/CA3119339A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/00042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3119339A 2018-12-12 2019-12-12 Anellosomes for delivering intracellular therapeutic modalities Pending CA3119339A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862778851P 2018-12-12 2018-12-12
US201862778866P 2018-12-12 2018-12-12
US62/778,851 2018-12-12
US62/778,866 2018-12-12
PCT/US2019/065874 WO2020123753A2 (en) 2018-12-12 2019-12-12 Anellosomes for delivering intracellular therapeutic modalities

Publications (1)

Publication Number Publication Date
CA3119339A1 true CA3119339A1 (en) 2020-06-18

Family

ID=69160334

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3119339A Pending CA3119339A1 (en) 2018-12-12 2019-12-12 Anellosomes for delivering intracellular therapeutic modalities

Country Status (11)

Country Link
US (1) US20220040117A1 (enExample)
EP (1) EP3894567A2 (enExample)
JP (2) JP2022514501A (enExample)
KR (1) KR20210131308A (enExample)
CN (1) CN114127302A (enExample)
AU (1) AU2019396516A1 (enExample)
BR (1) BR112021009282A2 (enExample)
CA (1) CA3119339A1 (enExample)
IL (1) IL283771A (enExample)
MX (1) MX2021006941A (enExample)
WO (1) WO2020123753A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021010925A2 (pt) * 2018-12-12 2021-08-31 Flagship Pioneering Innovations V, Inc Anelossomos para entrega de modalidades terapêuticas de substituição de proteína
US20220042042A1 (en) * 2018-12-12 2022-02-10 Flagship Pioneering Innovations V, Inc. Anellosomes and methods of use
CN116075591A (zh) * 2020-06-12 2023-05-05 旗舰先锋创新V股份有限公司 串联型指环病毒构建体
EP4447945A2 (en) * 2021-12-15 2024-10-23 Flagship Pioneering Innovations V, Inc. Surface-modified viral particles and modular viral particles
TW202505030A (zh) * 2023-06-14 2025-02-01 美商旗艦先鋒創新公司 用於遞送效應物至中樞神經系統之指環載體
WO2025080985A1 (en) 2023-10-13 2025-04-17 Flagship Pioneering Innovations V, Inc. Tissue specific anellovector delivery

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395472B1 (en) * 1999-02-05 2002-05-28 Abbott Laboratories Methods of utilizing the TT virus
JP2020524993A (ja) * 2017-06-13 2020-08-27 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド クロンを含む組成物及びその使用

Also Published As

Publication number Publication date
EP3894567A2 (en) 2021-10-20
JP2022514501A (ja) 2022-02-14
JP2024102242A (ja) 2024-07-30
KR20210131308A (ko) 2021-11-02
IL283771A (en) 2021-07-29
US20220040117A1 (en) 2022-02-10
BR112021009282A2 (pt) 2021-08-17
WO2020123753A2 (en) 2020-06-18
AU2019396516A1 (en) 2021-05-27
CN114127302A (zh) 2022-03-01
WO2020123753A3 (en) 2020-07-23
MX2021006941A (es) 2021-11-17

Similar Documents

Publication Publication Date Title
CA3119531A1 (en) Anellosomes for delivering secreted therapeutic modalities
CA3119814A1 (en) Anellosomes for delivering protein replacement therapeutic modalities
CA3121528A1 (en) Anellosomes and methods of use
CA3119339A1 (en) Anellosomes for delivering intracellular therapeutic modalities
CA3066750A1 (en) Compositions comprising curons and uses thereof
KR20220155981A (ko) 미성숙 종결 코돈-매개 장애를 치료하기 위한 방법 및 조성물
CN103476399A (zh) 药剂递送粒子及其制造方法
AU2021372533A1 (en) Chicken anemia virus (cav)-based vectors
KR20230036110A (ko) 탠덤 아넬로바이러스 구축물
KR20230124682A (ko) Rna를 봉입하는 아넬로바이러스 캡시드의 시험관 내어셈블리
KR20230041686A (ko) 아넬로바이러스를 확인 및 특징화하는 방법 및 이의 용도
EP4100067A1 (en) Mirna-485 inhibitor for gene upregulation
EP4048798B1 (en) Adenovirus comprising a modified adenovirus hexon protein
US20230121720A1 (en) Diagnostic methods using pcg-1a expression
US20230119699A1 (en) Diagnostic methods using sirt1 expression
WO2025241027A1 (en) Vectors encapsidating nucleic acids, production methods and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220726

EEER Examination request

Effective date: 20220726

EEER Examination request

Effective date: 20220726

EEER Examination request

Effective date: 20220726

EEER Examination request

Effective date: 20220726